Breaking News

Monday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
Bluebird Bio participates in a conference call with Cowen » 16:34
05/10/21
05/10
16:34
05/10/21
16:34
BLUE

Bluebird Bio

$28.41 /

-2.065 (-6.78%)

Biotech Analyst Werber…

Biotech Analyst Werber holds a conference call with management on May 14 at 11:30 am hosted by Cowen.

ShowHide Related Items >><<
BLUE Bluebird Bio
$28.41 /

-2.065 (-6.78%)

BLUE Bluebird Bio
$28.41 /

-2.065 (-6.78%)

04/21/21 BMO Capital
Bluebird Bio price target lowered to $31 from $35 at BMO Capital
04/20/21 Oppenheimer
Bluebird reimbursement talks not helped by lingering concerns, says Oppenheimer
03/29/21 BMO Capital
Bluebird Bio price target raised to $35 from $31 at BMO Capital
03/29/21 Mizuho
Bluebird Bio approval could improve sentiment on shares, says Mizuho
BLUE Bluebird Bio
$28.41 /

-2.065 (-6.78%)

  • 19
    May
BLUE Bluebird Bio
$28.41 /

-2.065 (-6.78%)

BLUE Bluebird Bio
$28.41 /

-2.065 (-6.78%)

BLUE Bluebird Bio
$28.41 /

-2.065 (-6.78%)

Over a week ago
Earnings
Bluebird Bio reports Q1 EPS ($3.07), consensus ($3.01) » 16:34
05/05/21
05/05
16:34
05/05/21
16:34
BLUE

Bluebird Bio

$29.22 /

-0.685 (-2.29%)

Reports Q1 revenue…

Reports Q1 revenue $12.8M, consensus $11.37M. Cash, cash equivalents and marketable securities as of March 31, 2021 and December 31, 2020 were $1.09 billion and $1.27 billion, respectively. The decrease in cash, cash equivalents and marketable securities is primarily related to cash used in support of ordinary course operating activities.

ShowHide Related Items >><<
BLUE Bluebird Bio
$29.22 /

-0.685 (-2.29%)

BLUE Bluebird Bio
$29.22 /

-0.685 (-2.29%)

04/21/21 BMO Capital
Bluebird Bio price target lowered to $31 from $35 at BMO Capital
04/20/21 Oppenheimer
Bluebird reimbursement talks not helped by lingering concerns, says Oppenheimer
03/29/21 BMO Capital
Bluebird Bio price target raised to $35 from $31 at BMO Capital
03/29/21 Mizuho
Bluebird Bio approval could improve sentiment on shares, says Mizuho
BLUE Bluebird Bio
$29.22 /

-0.685 (-2.29%)

  • 19
    May
BLUE Bluebird Bio
$29.22 /

-0.685 (-2.29%)

BLUE Bluebird Bio
$29.22 /

-0.685 (-2.29%)

BLUE Bluebird Bio
$29.22 /

-0.685 (-2.29%)

Recommendations
Bluebird Bio price target lowered to $31 from $35 at BMO Capital » 09:21
04/21/21
04/21
09:21
04/21/21
09:21
BLUE

Bluebird Bio

$27.83 /

-0.14 (-0.50%)

BMO Capital analyst…

BMO Capital analyst Matthew Luchini lowered the firm's price target on Bluebird Bio to $31 from $35 and keeps a Market Perform rating on the shares. The analyst is updating his model to reflect lower E.U. LentiGlobin sales, with the company's failure to secure reimbursement for Zynteglo in Germany increasing program risk and raising questions about pricing broadly, Luchini tells investors in a research note.

ShowHide Related Items >><<
BLUE Bluebird Bio
$27.83 /

-0.14 (-0.50%)

BLUE Bluebird Bio
$27.83 /

-0.14 (-0.50%)

04/20/21 Oppenheimer
Bluebird reimbursement talks not helped by lingering concerns, says Oppenheimer
03/29/21 BMO Capital
Bluebird Bio price target raised to $35 from $31 at BMO Capital
03/29/21 Mizuho
Bluebird Bio approval could improve sentiment on shares, says Mizuho
03/29/21 Piper Sandler
Bluebird Bio price target raised to $35 from $30 at Piper Sandler
BLUE Bluebird Bio
$27.83 /

-0.14 (-0.50%)

  • 19
    May
BLUE Bluebird Bio
$27.83 /

-0.14 (-0.50%)

BLUE Bluebird Bio
$27.83 /

-0.14 (-0.50%)

BLUE Bluebird Bio
$27.83 /

-0.14 (-0.50%)

Recommendations
Bluebird reimbursement talks not helped by lingering concerns, says Oppenheimer » 13:30
04/20/21
04/20
13:30
04/20/21
13:30
BLUE

Bluebird Bio

$27.92 /

-0.05 (-0.18%)

Bluebird Bio provided a…

Bluebird Bio provided a business update on its Lentiglobin-based gene therapy programs today and a suspected case of myelodysplastic syndrome in the HGB-206 study, announced in February, has been formally reclassified as non-malignant anemia by the investigator, Oppenheimer analyst Mark Breidenbach tells investors in a research note. This means only two malignancies have been observed in the HGB-206 trial of bb1111 in sickle cell disease, one of which was likely attributable to busulfan preconditioning and management believes the other case was unlikely related to treatment, says the analyst. Breidenbach believes that while the reclassification improves the product's safety profile, lingering reputational and regulatory concerns over Bluebird's gene therapy pipeline are "unlikely to help with development timelines or reimbursement discussions for Zynteglo, which have recently stalled in Germany." He reiterates a Perform rating on the shares.

ShowHide Related Items >><<
BLUE Bluebird Bio
$27.92 /

-0.05 (-0.18%)

BLUE Bluebird Bio
$27.92 /

-0.05 (-0.18%)

03/29/21 BMO Capital
Bluebird Bio price target raised to $35 from $31 at BMO Capital
03/29/21 Mizuho
Bluebird Bio approval could improve sentiment on shares, says Mizuho
03/29/21 Piper Sandler
Bluebird Bio price target raised to $35 from $30 at Piper Sandler
03/17/21 Stifel
Stifel says Bluebird Bio CMO exit 'a bit concerning but not thesis changing'
BLUE Bluebird Bio
$27.92 /

-0.05 (-0.18%)

  • 19
    May
BLUE Bluebird Bio
$27.92 /

-0.05 (-0.18%)

BLUE Bluebird Bio
$27.92 /

-0.05 (-0.18%)

BLUE Bluebird Bio
$27.92 /

-0.05 (-0.18%)

Hot Stocks
Bluebird Bio provides update on severe genetic disease programs and business ops » 07:35
04/20/21
04/20
07:35
04/20/21
07:35
BLUE

Bluebird Bio

$27.97 /

-0.31 (-1.10%)

bluebird bio announced …

bluebird bio announced business and program updates across its severe genetic disease portfolio including a revised diagnosis for the previously reported case of myelodysplastic syndrome in its Phase 1/2 study of LentiGlobin for sickle cell disease , the company's decision to withdraw ZYNTEGLO , betibeglogene autotemcel, beti-cel) for transfusion-dependent beta-thalassemia rom the German market and a targeted reshaping of its workforce intended to enable the company to advance its late-stage gene therapy programs. he case of MDS reported in February in a patient from Group C of the Phase 1/2 HGB-206 study of LentiGlobin gene therapy for SCD has been further assessed following the review of results from additional tests. The treating investigator has concluded this is not a case of MDS and has revised the diagnosis to transfusion-dependent anemia. bluebird bio has reported this update to regulatory agencies and study investigators. The company continues to work with the treating investigator to determine the potential cause of this patient's anemia.Last month, the company reported that it is very unlikely the suspected unexpected serious adverse reaction of acute myeloid leukemia reported in the HGB-206 study of LentiGlobin for SCD was related to the BB305 lentiviral vector . This assessment, along with the re-classification of the originally reported MDS case to transfusion-dependent anemia are important steps in bluebird bio's path to seeking removal of the clinical hold on studies HGB-206 and HGB-210 of LentiGlobin for SCD. bluebird bio continues to work with regulators to resume its clinical studies in sickle cell disease as well as to remove the clinical hold for HGB-207 and HGB-212 clinical studies of beti-cel for beta-thalassemia, with potential lift of all clinical holds in mid-2021.

ShowHide Related Items >><<
BLUE Bluebird Bio
$27.97 /

-0.31 (-1.10%)

BLUE Bluebird Bio
$27.97 /

-0.31 (-1.10%)

03/29/21 BMO Capital
Bluebird Bio price target raised to $35 from $31 at BMO Capital
03/29/21 Mizuho
Bluebird Bio approval could improve sentiment on shares, says Mizuho
03/29/21 Piper Sandler
Bluebird Bio price target raised to $35 from $30 at Piper Sandler
03/17/21 Stifel
Stifel says Bluebird Bio CMO exit 'a bit concerning but not thesis changing'
BLUE Bluebird Bio
$27.97 /

-0.31 (-1.10%)

  • 19
    May
BLUE Bluebird Bio
$27.97 /

-0.31 (-1.10%)

BLUE Bluebird Bio
$27.97 /

-0.31 (-1.10%)

BLUE Bluebird Bio
$27.97 /

-0.31 (-1.10%)

Over a month ago
Conference/Events
Alliance for Regenerative Medicine to hold a virtual meeting » 04:55
04/09/21
04/09
04:55
04/09/21
04:55
BLUE

Bluebird Bio

$28.86 /

-1.2 (-3.99%)

, GILD

Gilead

$65.03 /

-0.56 (-0.85%)

, TMO

Thermo Fisher

$471.57 /

+5.26 (+1.13%)

, SGTX

Sigilon Therapeutics

$17.81 /

-0.5 (-2.73%)

, ADAP

Adaptimmune

$5.12 /

+0.16 (+3.23%)

, AGTC

Applied Genetic

$4.57 /

+0.115 (+2.58%)

, ATRA

Atara Biotherapeutics

$14.18 /

-0.035 (-0.25%)

, CABA

Cabaletta Bio

$10.77 /

+0.155 (+1.46%)

, FLXN

Flexion

$8.30 /

-0.03 (-0.36%)

, DTIL

Precision BioSciences

$8.94 /

+0.025 (+0.28%)

, DOV

Dover

$138.50 /

-0.465 (-0.33%)

, GNPX

Genprex

$4.88 /

+0.805 (+19.78%)

, DBTX

Decibel Therapeutics

$10.71 /

-0.35 (-3.16%)

, CYRX

Cryoport

$53.88 /

+2.68 (+5.23%)

, GLW

Corning

$44.57 /

+0.27 (+0.61%)

, FTV

Fortive

$70.23 /

-1.16 (-1.62%)

, KRYS

Krystal Biotech

$73.50 /

-0.25 (-0.34%)

, NVO

Novo Nordisk

$69.24 /

+1.375 (+2.03%)

, NVS

Novartis

$87.02 /

+0.705 (+0.82%)

, ORTX

Orchard Therapeutics

$6.96 /

+0.09 (+1.31%)

, MRK

Merck

$75.48 /

-0.65 (-0.85%)

, MEDP

Medpace

$169.50 /

+1.6 (+0.95%)

, IOVA

Iovance Biotherapeutics

$31.30 /

+0.31 (+1.00%)

, FOLD

Amicus

$9.27 /

-0.0999 (-1.07%)

Cell & Gene Virtual…

Cell & Gene Virtual Meeting on the Mediterranean will be held on April 6-9. Webcast Link

ShowHide Related Items >><<
TMO Thermo Fisher
$471.57 /

+5.26 (+1.13%)

SGTX Sigilon Therapeutics
$17.81 /

-0.5 (-2.73%)

ORTX Orchard Therapeutics
$6.96 /

+0.09 (+1.31%)

NVS Novartis
$87.02 /

+0.705 (+0.82%)

NVO Novo Nordisk
$69.24 /

+1.375 (+2.03%)

MRK Merck
$75.48 /

-0.65 (-0.85%)

KRYS Krystal Biotech
$73.50 /

-0.25 (-0.34%)

IOVA Iovance Biotherapeutics
$31.30 /

+0.31 (+1.00%)

GNPX Genprex
$4.88 /

+0.805 (+19.78%)

GLW Corning
$44.57 /

+0.27 (+0.61%)

GILD Gilead
$65.03 /

-0.56 (-0.85%)

FTV Fortive
$70.23 /

-1.16 (-1.62%)

FOLD Amicus
$9.27 /

-0.0999 (-1.07%)

FLXN Flexion
$8.30 /

-0.03 (-0.36%)

DTIL Precision BioSciences
$8.94 /

+0.025 (+0.28%)

DOV Dover
$138.50 /

-0.465 (-0.33%)

DBTX Decibel Therapeutics
$10.71 /

-0.35 (-3.16%)

CYRX Cryoport
$53.88 /

+2.68 (+5.23%)

CABA Cabaletta Bio
$10.77 /

+0.155 (+1.46%)

BLUE Bluebird Bio
$28.86 /

-1.2 (-3.99%)

ATRA Atara Biotherapeutics
$14.18 /

-0.035 (-0.25%)

AGTC Applied Genetic
$4.57 /

+0.115 (+2.58%)

ADAP Adaptimmune
$5.12 /

+0.16 (+3.23%)

BLUE Bluebird Bio
$28.86 /

-1.2 (-3.99%)

03/29/21 BMO Capital
Bluebird Bio price target raised to $35 from $31 at BMO Capital
03/29/21 Mizuho
Bluebird Bio approval could improve sentiment on shares, says Mizuho
03/29/21 Piper Sandler
Bluebird Bio price target raised to $35 from $30 at Piper Sandler
03/17/21 Stifel
Stifel says Bluebird Bio CMO exit 'a bit concerning but not thesis changing'
GILD Gilead
$65.03 /

-0.56 (-0.85%)

04/01/21
Fly Intel: Top five analyst upgrades
04/01/21 Bernstein
Gilead upgraded to Outperform from Market Perform at Bernstein
03/30/21 Redburn
Gilead upgraded to Buy from Neutral at Redburn
03/15/21 Mizuho
Merck's Gilead collaboration likely to broaden reach of islatravir, says Mizuho
TMO Thermo Fisher
$471.57 /

+5.26 (+1.13%)

03/29/21 UBS
Thermo Fisher price target lowered to $560 from $588 at UBS
03/18/21 KeyBanc
Thermo Fisher upgraded to Overweight at KeyBanc after Sartorius guidance
03/18/21 KeyBanc
Thermo Fisher upgraded to Overweight from Sector Weight at KeyBanc
03/02/21 Barclays
Thermo Fisher initiated with an Overweight at Barclays
SGTX Sigilon Therapeutics
$17.81 /

-0.5 (-2.73%)

12/29/20 Barclays
Sigilon Therapeutics initiated with an Overweight at Barclays
12/29/20 Morgan Stanley
Sigilon Therapeutics initiated with an Equal Weight at Morgan Stanley
12/29/20 Jefferies
Sigilon Therapeutics initiated with a Buy at Jefferies
ADAP Adaptimmune
$5.12 /

+0.16 (+3.23%)

08/12/20 Piper Sandler
TCR2 Therapeutics initiated with an Overweight at Piper Sandler
06/01/20 Mizuho
Adaptimmune price target raised to $9 from $3 at Mizuho
05/29/20 JonesTrading
JonesTrading upgrades Adaptimmune to Buy after data alleviates 'key concern'
05/29/20 JonesTrading
Adaptimmune upgraded to Buy from Hold at JonesTrading
AGTC Applied Genetic
$4.57 /

+0.115 (+2.58%)

03/01/21 Stifel
Applied Genetic initiated with a Buy at Stifel
02/02/21 H.C. Wainwright
Applied Genetic price target raised to $24 from $18 at H.C. Wainwright
02/01/21 Roth Capital
Applied Genetic price target raised to $35 from $30 at Roth Capital
11/17/20 Roth Capital
Applied Genetic price target raised to $30 from $26 at Roth Capital
ATRA Atara Biotherapeutics
$14.18 /

-0.035 (-0.25%)

03/25/21 Evercore ISI
Viracta Therapeutics initiated with an Outperform at Evercore ISI
03/02/21 Citi
Atara Biotherapeutics upgraded to Buy at Citi following 35% pullback
03/02/21 Citi
Atara Biotherapeutics upgraded to Buy from Neutral at Citi
01/04/21 Roth Capital
Roth keeps Buy rating on Atara Biotherapeutics after filing delay
CABA Cabaletta Bio
$10.77 /

+0.155 (+1.46%)

03/17/21 H.C. Wainwright
Cabaletta Bio price target raised to $22 from $20 at H.C. Wainwright
01/08/21 Chardan
Cabaletta Bio initiated with a Buy at Chardan
10/13/20 H.C. Wainwright
Cabaletta Bio initiated with a Buy at H.C. Wainwright
FLXN Flexion
$8.30 /

-0.03 (-0.36%)

04/06/21 RBC Capital
Flexion transferred with an Outperform at RBC Capital
08/20/20 Goldman Sachs
Flexion initiated with a Neutral at Goldman Sachs
07/30/20 Oppenheimer
Flexion initiated with an Outperform at Oppenheimer
07/29/20
Fly Intel: Top five analyst initiations
DTIL Precision BioSciences
$8.94 /

+0.025 (+0.28%)

04/06/21 Stifel
Stifel sees Precision BioSciences' CEO transition as 'disconcerting'
02/24/21
Fly Intel: Top five analyst initiations
02/24/21 JonesTrading
Precision BioSciences initiated with a Buy at JonesTrading
01/29/21 JPMorgan
Precision BioSciences price target raised to $14 from $10 at JPMorgan
DOV Dover
$138.50 /

-0.465 (-0.33%)

04/06/21 Barclays
Dover price target raised to $155 from $145 at Barclays
01/28/21 Baird
Dover price target raised to $147 from $140 at Baird
01/28/21 Baird
Dover results a solid beat with guidance above consensus, says Baird
01/05/21 Barclays
Dover price target raised to $141 from $138 at Barclays
GNPX Genprex
$4.88 /

+0.805 (+19.78%)

01/26/21 National Securities
Genprex initiated with a Buy at National Securities
04/22/20 Alliance Global Partners
Genprex initiated with a Buy at Alliance Global Partners
DBTX Decibel Therapeutics
$10.71 /

-0.35 (-3.16%)

03/09/21 Citi
Decibel Therapeutics initiated with a Buy at Citi
03/09/21 SVB Leerink
Decibel Therapeutics initiated with an Outperform at SVB Leerink
03/09/21 Barclays
Decibel Therapeutics initiated with an Overweight at Barclays
03/09/21 BMO Capital
Decibel Therapeutics initiated with an Outperform at BMO Capital
CYRX Cryoport
$53.88 /

+2.68 (+5.23%)

03/15/21
Fly Intel: Top five analyst initiations
03/15/21 UBS
Cryoport initiated with a Buy at UBS
03/02/21
Fly Intel: Top five analyst initiations
03/02/21 Needham
Cryoport assumed with a Buy at Needham
GLW Corning
$44.57 /

+0.27 (+0.61%)

04/07/21 Argus
Corning price target raised to $54 from $42 at Argus
01/28/21 Oppenheimer
Corning upgraded to Outperform from Perform at Oppenheimer
01/14/21 Barclays
Corning upgraded to Overweight with $44 target at Barclays
01/14/21 Barclays
Corning upgraded to Overweight from Equal Weight at Barclays
FTV Fortive
$70.23 /

-1.16 (-1.62%)

04/06/21 Barclays
Fortive price target raised to $73 from $72 at Barclays
02/17/21
Fly Intel: Top five analyst downgrades
02/17/21 Morgan Stanley
Fortive downgraded to Equal Weight at Morgan Stanley after re-rating
02/17/21 Morgan Stanley
Fortive downgraded to Equal Weight from Overweight at Morgan Stanley
KRYS Krystal Biotech
$73.50 /

-0.25 (-0.34%)

03/01/21 H.C. Wainwright
Krystal Biotech price target raised to $103 from $84 at H.C. Wainwright
03/01/21 William Blair
Krystal Biotech has 'catalyst-rich year ahead,' says William Blair
02/09/21 JonesTrading
Krystal Biotech initiated with a Buy at JonesTrading
01/15/21 Chardan
Krystal Biotech named a 'Top Pick for 2021' at Chardan
NVO Novo Nordisk
$69.24 /

+1.375 (+2.03%)

02/11/21 UBS
Novo Nordisk price target raised to DKK 425 from DKK 415 at UBS
02/04/21 Barclays
Novo Nordisk price target raised to DKK 495 from DKK 485 at Barclays
01/20/21 Citi
Citi opens 'Positive Catalyst Watch' on Novo Nordisk
01/20/21 Credit Suisse
Novo Nordisk downgraded to Neutral from Outperform at Credit Suisse
NVS Novartis
$87.02 /

+0.705 (+0.82%)

04/05/21 Morgan Stanley
Regenxbio AAV9 patent challenged by Passage Bio, says Morgan Stanley
03/23/21 Societe Generale
Novartis price target raised to CHF 107 from CHF 104 at Societe Generale
03/22/21 Bernstein
Novartis initiated with a Market Perform at Bernstein
03/10/21
Fly Intel: Top five analyst downgrades
ORTX Orchard Therapeutics
$6.96 /

+0.09 (+1.31%)

03/10/21 Stifel
Stifel says Bluebird update on AML provides 'some relief' to other LV players
03/02/21 JPMorgan
Orchard Therapeutics assumed with an Overweight at JPMorgan
03/01/21 Stifel
Orchard Therapeutics initiated with a Buy at Stifel
02/18/21 Goldman Sachs
Orchard selloff on Bluebird Bio news overdone, says Goldman Sachs
MRK Merck
$75.48 /

-0.65 (-0.85%)

04/08/21 Alliance Global Partners
Alliance Global Partners sees Fast Track for Immutep efti as meaningful positive
04/08/21 H.C. Wainwright
Alkermes collaboration not as big as investors wanted, says H.C. Wainwright
04/07/21 Mizuho
Mizuho sees Alkermes, Merck collaboration as important next step for nemvaleukin
04/06/21 RBC Capital
Merck transferred with a Sector Perform at RBC Capital
MEDP Medpace
$169.50 /

+1.6 (+0.95%)

02/17/21 Truist
Medpace price target raised to $180 from $135 at Truist
02/16/21 Credit Suisse
Medpace price target raised to $178 from $155 at Credit Suisse
10/02/20 Truist
Medpace upgraded to Buy from Hold at Truist
07/29/20 Truist
Medpace price target raised to $124 from $95 at SunTrust
IOVA Iovance Biotherapeutics
$31.30 /

+0.31 (+1.00%)

03/08/21 H.C. Wainwright
Iovance Biotherapeutics upgraded to Buy from Neutral at H.C. Wainwright
01/29/21 Baird
Iovance Biotherapeutics assumed at Outperform at Baird
01/14/21 Oppenheimer
Iovance Biotherapeutics price target raised to $57 from $43 at Oppenheimer
12/17/20 Barclays
Iovance Biotherapeutics price target raised to $55 from $43 at Barclays
FOLD Amicus
$9.27 /

-0.0999 (-1.07%)

03/01/21 Stifel
Amicus initiated with a Hold at Stifel
02/12/21
Fly Intel: Top five analyst downgrades
02/12/21 JPMorgan
Amicus downgraded to Neutral on Pompe disease miss at JPMorgan
02/12/21 SVB Leerink
Amicus downgraded to Market Perform from Outperform at SVB Leerink
TMO Thermo Fisher
$471.57 /

+5.26 (+1.13%)

SGTX Sigilon Therapeutics
$17.81 /

-0.5 (-2.73%)

ORTX Orchard Therapeutics
$6.96 /

+0.09 (+1.31%)

NVS Novartis
$87.02 /

+0.705 (+0.82%)

NVO Novo Nordisk
$69.24 /

+1.375 (+2.03%)

MRK Merck
$75.48 /

-0.65 (-0.85%)

MEDP Medpace
$169.50 /

+1.6 (+0.95%)

KRYS Krystal Biotech
$73.50 /

-0.25 (-0.34%)

IOVA Iovance Biotherapeutics
$31.30 /

+0.31 (+1.00%)

GLW Corning
$44.57 /

+0.27 (+0.61%)

GILD Gilead
$65.03 /

-0.56 (-0.85%)

FTV Fortive
$70.23 /

-1.16 (-1.62%)

FOLD Amicus
$9.27 /

-0.0999 (-1.07%)

FLXN Flexion
$8.30 /

-0.03 (-0.36%)

DTIL Precision BioSciences
$8.94 /

+0.025 (+0.28%)

DOV Dover
$138.50 /

-0.465 (-0.33%)

CYRX Cryoport
$53.88 /

+2.68 (+5.23%)

CABA Cabaletta Bio
$10.77 /

+0.155 (+1.46%)

BLUE Bluebird Bio
$28.86 /

-1.2 (-3.99%)

ATRA Atara Biotherapeutics
$14.18 /

-0.035 (-0.25%)

AGTC Applied Genetic
$4.57 /

+0.115 (+2.58%)

ADAP Adaptimmune
$5.12 /

+0.16 (+3.23%)

  • 12
    Feb
  • 03
    Feb
  • 28
    Jan
  • 21
    Jan
  • 09
    Dec
  • 04
    Dec
  • 02
    Jun
  • 29
    May
  • 27
    May
  • 21
    May
  • 19
    May
  • 19
    May
TMO Thermo Fisher
$471.57 /

+5.26 (+1.13%)

NVS Novartis
$87.02 /

+0.705 (+0.82%)

MRK Merck
$75.48 /

-0.65 (-0.85%)

GLW Corning
$44.57 /

+0.27 (+0.61%)

GILD Gilead
$65.03 /

-0.56 (-0.85%)

FTV Fortive
$70.23 /

-1.16 (-1.62%)

FOLD Amicus
$9.27 /

-0.0999 (-1.07%)

CYRX Cryoport
$53.88 /

+2.68 (+5.23%)

BLUE Bluebird Bio
$28.86 /

-1.2 (-3.99%)

TMO Thermo Fisher
$471.57 /

+5.26 (+1.13%)

SGTX Sigilon Therapeutics
$17.81 /

-0.5 (-2.73%)

NVS Novartis
$87.02 /

+0.705 (+0.82%)

MRK Merck
$75.48 /

-0.65 (-0.85%)

GLW Corning
$44.57 /

+0.27 (+0.61%)

GILD Gilead
$65.03 /

-0.56 (-0.85%)

FOLD Amicus
$9.27 /

-0.0999 (-1.07%)

DTIL Precision BioSciences
$8.94 /

+0.025 (+0.28%)

DOV Dover
$138.50 /

-0.465 (-0.33%)

DBTX Decibel Therapeutics
$10.71 /

-0.35 (-3.16%)

BLUE Bluebird Bio
$28.86 /

-1.2 (-3.99%)

ATRA Atara Biotherapeutics
$14.18 /

-0.035 (-0.25%)

AGTC Applied Genetic
$4.57 /

+0.115 (+2.58%)

NVO Novo Nordisk
$69.24 /

+1.375 (+2.03%)

MRK Merck
$75.48 /

-0.65 (-0.85%)

GLW Corning
$44.57 /

+0.27 (+0.61%)

GILD Gilead
$65.03 /

-0.56 (-0.85%)

FOLD Amicus
$9.27 /

-0.0999 (-1.07%)

CABA Cabaletta Bio
$10.77 /

+0.155 (+1.46%)

BLUE Bluebird Bio
$28.86 /

-1.2 (-3.99%)

Conference/Events
Alliance for Regenerative Medicine to hold a virtual meeting » 04:55
04/08/21
04/08
04:55
04/08/21
04:55
BLUE

Bluebird Bio

$30.06 /

-0.1 (-0.33%)

, GILD

Gilead

$65.59 /

-0.67 (-1.01%)

, TMO

Thermo Fisher

$466.27 /

-2.75 (-0.59%)

, SGTX

Sigilon Therapeutics

$18.35 /

-0.64 (-3.37%)

, ADAP

Adaptimmune

$4.96 /

-0.3 (-5.70%)

, AGTC

Applied Genetic

$4.45 /

-0.29 (-6.12%)

, ATRA

Atara Biotherapeutics

$14.22 /

+0.065 (+0.46%)

, CABA

Cabaletta Bio

$10.54 /

-1.02 (-8.82%)

, FLXN

Flexion

$8.34 /

-0.37 (-4.25%)

, DTIL

Precision BioSciences

$8.92 /

-0.34 (-3.67%)

, DOV

Dover

$139.17 /

-0.27 (-0.19%)

, GNPX

Genprex

$4.07 /

-0.23 (-5.35%)

, DBTX

Decibel Therapeutics

$11.06 /

-0.44 (-3.83%)

, CYRX

Cryoport

$51.23 /

-0.27 (-0.52%)

, GLW

Corning

$44.30 /

-0.38 (-0.85%)

, FTV

Fortive

$71.39 /

+0.25 (+0.35%)

, KRYS

Krystal Biotech

$73.72 /

-0.23 (-0.31%)

, NVO

Novo Nordisk

$67.86 /

-0.185 (-0.27%)

, NVS

Novartis

$86.30 /

-0.09 (-0.10%)

, ORTX

Orchard Therapeutics

$6.87 /

-0.22 (-3.10%)

, MRK

Merck

$76.13 /

+0.34 (+0.45%)

, MEDP

Medpace

$167.40 /

-7.13 (-4.09%)

, IOVA

Iovance Biotherapeutics

$31.02 /

-0.98 (-3.06%)

, FOLD

Amicus

$9.37 /

-0.19 (-1.99%)

Cell & Gene Virtual…

Cell & Gene Virtual Meeting on the Mediterranean will be held on April 6-9. Webcast Link

ShowHide Related Items >><<
TMO Thermo Fisher
$466.27 /

-2.75 (-0.59%)

SGTX Sigilon Therapeutics
$18.35 /

-0.64 (-3.37%)

ORTX Orchard Therapeutics
$6.87 /

-0.22 (-3.10%)

NVS Novartis
$86.30 /

-0.09 (-0.10%)

NVO Novo Nordisk
$67.86 /

-0.185 (-0.27%)

MRK Merck
$76.13 /

+0.34 (+0.45%)

KRYS Krystal Biotech
$73.72 /

-0.23 (-0.31%)

IOVA Iovance Biotherapeutics
$31.02 /

-0.98 (-3.06%)

GNPX Genprex
$4.07 /

-0.23 (-5.35%)

GLW Corning
$44.30 /

-0.38 (-0.85%)

GILD Gilead
$65.59 /

-0.67 (-1.01%)

FTV Fortive
$71.39 /

+0.25 (+0.35%)

FOLD Amicus
$9.37 /

-0.19 (-1.99%)

FLXN Flexion
$8.34 /

-0.37 (-4.25%)

DTIL Precision BioSciences
$8.92 /

-0.34 (-3.67%)

DOV Dover
$139.17 /

-0.27 (-0.19%)

DBTX Decibel Therapeutics
$11.06 /

-0.44 (-3.83%)

CYRX Cryoport
$51.23 /

-0.27 (-0.52%)

CABA Cabaletta Bio
$10.54 /

-1.02 (-8.82%)

BLUE Bluebird Bio
$30.06 /

-0.1 (-0.33%)

ATRA Atara Biotherapeutics
$14.22 /

+0.065 (+0.46%)

AGTC Applied Genetic
$4.45 /

-0.29 (-6.12%)

ADAP Adaptimmune
$4.96 /

-0.3 (-5.70%)

BLUE Bluebird Bio
$30.06 /

-0.1 (-0.33%)

03/29/21 BMO Capital
Bluebird Bio price target raised to $35 from $31 at BMO Capital
03/29/21 Mizuho
Bluebird Bio approval could improve sentiment on shares, says Mizuho
03/29/21 Piper Sandler
Bluebird Bio price target raised to $35 from $30 at Piper Sandler
03/17/21 Stifel
Stifel says Bluebird Bio CMO exit 'a bit concerning but not thesis changing'
GILD Gilead
$65.59 /

-0.67 (-1.01%)

04/01/21
Fly Intel: Top five analyst upgrades
04/01/21 Bernstein
Gilead upgraded to Outperform from Market Perform at Bernstein
03/30/21 Redburn
Gilead upgraded to Buy from Neutral at Redburn
03/15/21 Mizuho
Merck's Gilead collaboration likely to broaden reach of islatravir, says Mizuho
TMO Thermo Fisher
$466.27 /

-2.75 (-0.59%)

03/29/21 UBS
Thermo Fisher price target lowered to $560 from $588 at UBS
03/18/21 KeyBanc
Thermo Fisher upgraded to Overweight at KeyBanc after Sartorius guidance
03/18/21 KeyBanc
Thermo Fisher upgraded to Overweight from Sector Weight at KeyBanc
03/02/21 Barclays
Thermo Fisher initiated with an Overweight at Barclays
SGTX Sigilon Therapeutics
$18.35 /

-0.64 (-3.37%)

12/29/20 Barclays
Sigilon Therapeutics initiated with an Overweight at Barclays
12/29/20 Morgan Stanley
Sigilon Therapeutics initiated with an Equal Weight at Morgan Stanley
12/29/20 Jefferies
Sigilon Therapeutics initiated with a Buy at Jefferies
ADAP Adaptimmune
$4.96 /

-0.3 (-5.70%)

08/12/20 Piper Sandler
TCR2 Therapeutics initiated with an Overweight at Piper Sandler
06/01/20 Mizuho
Adaptimmune price target raised to $9 from $3 at Mizuho
05/29/20 JonesTrading
JonesTrading upgrades Adaptimmune to Buy after data alleviates 'key concern'
05/29/20 JonesTrading
Adaptimmune upgraded to Buy from Hold at JonesTrading
AGTC Applied Genetic
$4.45 /

-0.29 (-6.12%)

03/01/21 Stifel
Applied Genetic initiated with a Buy at Stifel
02/02/21 H.C. Wainwright
Applied Genetic price target raised to $24 from $18 at H.C. Wainwright
02/01/21 Roth Capital
Applied Genetic price target raised to $35 from $30 at Roth Capital
11/17/20 Roth Capital
Applied Genetic price target raised to $30 from $26 at Roth Capital
ATRA Atara Biotherapeutics
$14.22 /

+0.065 (+0.46%)

03/25/21 Evercore ISI
Viracta Therapeutics initiated with an Outperform at Evercore ISI
03/02/21 Citi
Atara Biotherapeutics upgraded to Buy at Citi following 35% pullback
03/02/21 Citi
Atara Biotherapeutics upgraded to Buy from Neutral at Citi
01/04/21 Roth Capital
Roth keeps Buy rating on Atara Biotherapeutics after filing delay
CABA Cabaletta Bio
$10.54 /

-1.02 (-8.82%)

03/17/21 H.C. Wainwright
Cabaletta Bio price target raised to $22 from $20 at H.C. Wainwright
01/08/21 Chardan
Cabaletta Bio initiated with a Buy at Chardan
10/13/20 H.C. Wainwright
Cabaletta Bio initiated with a Buy at H.C. Wainwright
FLXN Flexion
$8.34 /

-0.37 (-4.25%)

04/06/21 RBC Capital
Flexion transferred with an Outperform at RBC Capital
08/20/20 Goldman Sachs
Flexion initiated with a Neutral at Goldman Sachs
07/30/20 Oppenheimer
Flexion initiated with an Outperform at Oppenheimer
07/29/20
Fly Intel: Top five analyst initiations
DTIL Precision BioSciences
$8.92 /

-0.34 (-3.67%)

04/06/21 Stifel
Stifel sees Precision BioSciences' CEO transition as 'disconcerting'
02/24/21
Fly Intel: Top five analyst initiations
02/24/21 JonesTrading
Precision BioSciences initiated with a Buy at JonesTrading
01/29/21 JPMorgan
Precision BioSciences price target raised to $14 from $10 at JPMorgan
DOV Dover
$139.17 /

-0.27 (-0.19%)

04/06/21 Barclays
Dover price target raised to $155 from $145 at Barclays
01/28/21 Baird
Dover price target raised to $147 from $140 at Baird
01/28/21 Baird
Dover results a solid beat with guidance above consensus, says Baird
01/05/21 Barclays
Dover price target raised to $141 from $138 at Barclays
GNPX Genprex
$4.07 /

-0.23 (-5.35%)

01/26/21 National Securities
Genprex initiated with a Buy at National Securities
04/22/20 Alliance Global Partners
Genprex initiated with a Buy at Alliance Global Partners
DBTX Decibel Therapeutics
$11.06 /

-0.44 (-3.83%)

03/09/21 Citi
Decibel Therapeutics initiated with a Buy at Citi
03/09/21 SVB Leerink
Decibel Therapeutics initiated with an Outperform at SVB Leerink
03/09/21 Barclays
Decibel Therapeutics initiated with an Overweight at Barclays
03/09/21 BMO Capital
Decibel Therapeutics initiated with an Outperform at BMO Capital
CYRX Cryoport
$51.23 /

-0.27 (-0.52%)

03/15/21
Fly Intel: Top five analyst initiations
03/15/21 UBS
Cryoport initiated with a Buy at UBS
03/02/21
Fly Intel: Top five analyst initiations
03/02/21 Needham
Cryoport assumed with a Buy at Needham
GLW Corning
$44.30 /

-0.38 (-0.85%)

04/07/21 Argus
Corning price target raised to $54 from $42 at Argus
01/28/21 Oppenheimer
Corning upgraded to Outperform from Perform at Oppenheimer
01/14/21 Barclays
Corning upgraded to Overweight with $44 target at Barclays
01/14/21 Barclays
Corning upgraded to Overweight from Equal Weight at Barclays
FTV Fortive
$71.39 /

+0.25 (+0.35%)

04/06/21 Barclays
Fortive price target raised to $73 from $72 at Barclays
02/17/21
Fly Intel: Top five analyst downgrades
02/17/21 Morgan Stanley
Fortive downgraded to Equal Weight at Morgan Stanley after re-rating
02/17/21 Morgan Stanley
Fortive downgraded to Equal Weight from Overweight at Morgan Stanley
KRYS Krystal Biotech
$73.72 /

-0.23 (-0.31%)

03/01/21 H.C. Wainwright
Krystal Biotech price target raised to $103 from $84 at H.C. Wainwright
03/01/21 William Blair
Krystal Biotech has 'catalyst-rich year ahead,' says William Blair
02/09/21 JonesTrading
Krystal Biotech initiated with a Buy at JonesTrading
01/15/21 Chardan
Krystal Biotech named a 'Top Pick for 2021' at Chardan
NVO Novo Nordisk
$67.86 /

-0.185 (-0.27%)

02/11/21 UBS
Novo Nordisk price target raised to DKK 425 from DKK 415 at UBS
02/04/21 Barclays
Novo Nordisk price target raised to DKK 495 from DKK 485 at Barclays
01/20/21 Citi
Citi opens 'Positive Catalyst Watch' on Novo Nordisk
01/20/21 Credit Suisse
Novo Nordisk downgraded to Neutral from Outperform at Credit Suisse
NVS Novartis
$86.30 /

-0.09 (-0.10%)

04/05/21 Morgan Stanley
Regenxbio AAV9 patent challenged by Passage Bio, says Morgan Stanley
03/23/21 Societe Generale
Novartis price target raised to CHF 107 from CHF 104 at Societe Generale
03/22/21 Bernstein
Novartis initiated with a Market Perform at Bernstein
03/10/21
Fly Intel: Top five analyst downgrades
ORTX Orchard Therapeutics
$6.87 /

-0.22 (-3.10%)

03/10/21 Stifel
Stifel says Bluebird update on AML provides 'some relief' to other LV players
03/02/21 JPMorgan
Orchard Therapeutics assumed with an Overweight at JPMorgan
03/01/21 Stifel
Orchard Therapeutics initiated with a Buy at Stifel
02/18/21 Goldman Sachs
Orchard selloff on Bluebird Bio news overdone, says Goldman Sachs
MRK Merck
$76.13 /

+0.34 (+0.45%)

04/07/21 Mizuho
Mizuho sees Alkermes, Merck collaboration as important next step for nemvaleukin
04/06/21 RBC Capital
Merck transferred with a Sector Perform at RBC Capital
04/01/21 Morgan Stanley
Merck cancer pipeline underappreciated and 'set to flow,' says Morgan Stanley
MEDP Medpace
$167.40 /

-7.13 (-4.09%)

02/17/21 Truist
Medpace price target raised to $180 from $135 at Truist
02/16/21 Credit Suisse
Medpace price target raised to $178 from $155 at Credit Suisse
10/02/20 Truist
Medpace upgraded to Buy from Hold at Truist
07/29/20 Truist
Medpace price target raised to $124 from $95 at SunTrust
IOVA Iovance Biotherapeutics
$31.02 /

-0.98 (-3.06%)

03/08/21 H.C. Wainwright
Iovance Biotherapeutics upgraded to Buy from Neutral at H.C. Wainwright
01/29/21 Baird
Iovance Biotherapeutics assumed at Outperform at Baird
01/14/21 Oppenheimer
Iovance Biotherapeutics price target raised to $57 from $43 at Oppenheimer
12/17/20 Barclays
Iovance Biotherapeutics price target raised to $55 from $43 at Barclays
FOLD Amicus
$9.37 /

-0.19 (-1.99%)

03/01/21 Stifel
Amicus initiated with a Hold at Stifel
02/12/21
Fly Intel: Top five analyst downgrades
02/12/21 JPMorgan
Amicus downgraded to Neutral on Pompe disease miss at JPMorgan
02/12/21 SVB Leerink
Amicus downgraded to Market Perform from Outperform at SVB Leerink
TMO Thermo Fisher
$466.27 /

-2.75 (-0.59%)

SGTX Sigilon Therapeutics
$18.35 /

-0.64 (-3.37%)

ORTX Orchard Therapeutics
$6.87 /

-0.22 (-3.10%)

NVS Novartis
$86.30 /

-0.09 (-0.10%)

NVO Novo Nordisk
$67.86 /

-0.185 (-0.27%)

MRK Merck
$76.13 /

+0.34 (+0.45%)

MEDP Medpace
$167.40 /

-7.13 (-4.09%)

KRYS Krystal Biotech
$73.72 /

-0.23 (-0.31%)

IOVA Iovance Biotherapeutics
$31.02 /

-0.98 (-3.06%)

GLW Corning
$44.30 /

-0.38 (-0.85%)

GILD Gilead
$65.59 /

-0.67 (-1.01%)

FTV Fortive
$71.39 /

+0.25 (+0.35%)

FOLD Amicus
$9.37 /

-0.19 (-1.99%)

FLXN Flexion
$8.34 /

-0.37 (-4.25%)

DTIL Precision BioSciences
$8.92 /

-0.34 (-3.67%)

DOV Dover
$139.17 /

-0.27 (-0.19%)

CYRX Cryoport
$51.23 /

-0.27 (-0.52%)

CABA Cabaletta Bio
$10.54 /

-1.02 (-8.82%)

BLUE Bluebird Bio
$30.06 /

-0.1 (-0.33%)

ATRA Atara Biotherapeutics
$14.22 /

+0.065 (+0.46%)

AGTC Applied Genetic
$4.45 /

-0.29 (-6.12%)

ADAP Adaptimmune
$4.96 /

-0.3 (-5.70%)

  • 12
    Feb
  • 03
    Feb
  • 28
    Jan
  • 21
    Jan
  • 09
    Dec
  • 04
    Dec
  • 02
    Jun
  • 29
    May
  • 27
    May
  • 21
    May
  • 19
    May
  • 19
    May
TMO Thermo Fisher
$466.27 /

-2.75 (-0.59%)

NVS Novartis
$86.30 /

-0.09 (-0.10%)

MRK Merck
$76.13 /

+0.34 (+0.45%)

GLW Corning
$44.30 /

-0.38 (-0.85%)

GILD Gilead
$65.59 /

-0.67 (-1.01%)

FTV Fortive
$71.39 /

+0.25 (+0.35%)

FOLD Amicus
$9.37 /

-0.19 (-1.99%)

CYRX Cryoport
$51.23 /

-0.27 (-0.52%)

BLUE Bluebird Bio
$30.06 /

-0.1 (-0.33%)

TMO Thermo Fisher
$466.27 /

-2.75 (-0.59%)

SGTX Sigilon Therapeutics
$18.35 /

-0.64 (-3.37%)

NVS Novartis
$86.30 /

-0.09 (-0.10%)

MRK Merck
$76.13 /

+0.34 (+0.45%)

GLW Corning
$44.30 /

-0.38 (-0.85%)

GILD Gilead
$65.59 /

-0.67 (-1.01%)

FOLD Amicus
$9.37 /

-0.19 (-1.99%)

DTIL Precision BioSciences
$8.92 /

-0.34 (-3.67%)

DOV Dover
$139.17 /

-0.27 (-0.19%)

DBTX Decibel Therapeutics
$11.06 /

-0.44 (-3.83%)

BLUE Bluebird Bio
$30.06 /

-0.1 (-0.33%)

ATRA Atara Biotherapeutics
$14.22 /

+0.065 (+0.46%)

AGTC Applied Genetic
$4.45 /

-0.29 (-6.12%)

NVO Novo Nordisk
$67.86 /

-0.185 (-0.27%)

MRK Merck
$76.13 /

+0.34 (+0.45%)

GLW Corning
$44.30 /

-0.38 (-0.85%)

GILD Gilead
$65.59 /

-0.67 (-1.01%)

FOLD Amicus
$9.37 /

-0.19 (-1.99%)

CABA Cabaletta Bio
$10.54 /

-1.02 (-8.82%)

BLUE Bluebird Bio
$30.06 /

-0.1 (-0.33%)

Conference/Events
Alliance for Regenerative Medicine to hold a virtual meeting » 04:55
04/07/21
04/07
04:55
04/07/21
04:55
BLUE

Bluebird Bio

$30.15 /

-0.95 (-3.05%)

, GILD

Gilead

$66.26 /

-0.09 (-0.14%)

, TMO

Thermo Fisher

$469.09 /

+3.53 (+0.76%)

, SGTX

Sigilon Therapeutics

$19.05 /

-0.965 (-4.82%)

, ADAP

Adaptimmune

$5.26 /

-0.35 (-6.24%)

, AGTC

Applied Genetic

$4.74 /

-0.26 (-5.20%)

, ATRA

Atara Biotherapeutics

$14.15 /

-0.53 (-3.61%)

, CABA

Cabaletta Bio

$11.21 /

-0.4 (-3.45%)

, FLXN

Flexion

$8.71 /

-0.11 (-1.25%)

, DTIL

Precision BioSciences

$9.23 /

-1.24 (-11.84%)

, DOV

Dover

$139.44 /

-0.74 (-0.53%)

, GNPX

Genprex

$4.29 /

+0.06 (+1.42%)

, DBTX

Decibel Therapeutics

$11.48 /

+0.09 (+0.79%)

, CYRX

Cryoport

$51.47 /

+1.1 (+2.18%)

, GLW

Corning

$44.68 /

-0.81 (-1.78%)

, FTV

Fortive

$71.18 /

-0.78 (-1.08%)

, KRYS

Krystal Biotech

$74.13 /

-4.6 (-5.84%)

, NVO

Novo Nordisk

$68.05 /

-0.235 (-0.34%)

, NVS

Novartis

$86.40 /

-0.89 (-1.02%)

, ORTX

Orchard Therapeutics

$7.09 /

-0.14 (-1.94%)

, MRK

Merck

$75.79 /

-1.21 (-1.57%)

, MEDP

Medpace

$171.71 /

+0.78 (+0.46%)

, IOVA

Iovance Biotherapeutics

$31.99 /

-0.16 (-0.50%)

, FOLD

Amicus

$9.56 /

-0.3848 (-3.87%)

Cell & Gene Virtual…

Cell & Gene Virtual Meeting on the Mediterranean will be held on April 6-9. Webcast Link

ShowHide Related Items >><<
TMO Thermo Fisher
$469.09 /

+3.53 (+0.76%)

SGTX Sigilon Therapeutics
$19.05 /

-0.965 (-4.82%)

ORTX Orchard Therapeutics
$7.09 /

-0.14 (-1.94%)

NVS Novartis
$86.40 /

-0.89 (-1.02%)

NVO Novo Nordisk
$68.05 /

-0.235 (-0.34%)

MRK Merck
$75.79 /

-1.21 (-1.57%)

KRYS Krystal Biotech
$74.13 /

-4.6 (-5.84%)

IOVA Iovance Biotherapeutics
$31.99 /

-0.16 (-0.50%)

GNPX Genprex
$4.29 /

+0.06 (+1.42%)

GLW Corning
$44.68 /

-0.81 (-1.78%)

GILD Gilead
$66.26 /

-0.09 (-0.14%)

FTV Fortive
$71.18 /

-0.78 (-1.08%)

FOLD Amicus
$9.56 /

-0.3848 (-3.87%)

FLXN Flexion
$8.71 /

-0.11 (-1.25%)

DTIL Precision BioSciences
$9.23 /

-1.24 (-11.84%)

DOV Dover
$139.44 /

-0.74 (-0.53%)

DBTX Decibel Therapeutics
$11.48 /

+0.09 (+0.79%)

CYRX Cryoport
$51.47 /

+1.1 (+2.18%)

CABA Cabaletta Bio
$11.21 /

-0.4 (-3.45%)

BLUE Bluebird Bio
$30.15 /

-0.95 (-3.05%)

ATRA Atara Biotherapeutics
$14.15 /

-0.53 (-3.61%)

AGTC Applied Genetic
$4.74 /

-0.26 (-5.20%)

ADAP Adaptimmune
$5.26 /

-0.35 (-6.24%)

BLUE Bluebird Bio
$30.15 /

-0.95 (-3.05%)

03/29/21 BMO Capital
Bluebird Bio price target raised to $35 from $31 at BMO Capital
03/29/21 Mizuho
Bluebird Bio approval could improve sentiment on shares, says Mizuho
03/29/21 Piper Sandler
Bluebird Bio price target raised to $35 from $30 at Piper Sandler
03/17/21 Stifel
Stifel says Bluebird Bio CMO exit 'a bit concerning but not thesis changing'
GILD Gilead
$66.26 /

-0.09 (-0.14%)

04/01/21
Fly Intel: Top five analyst upgrades
04/01/21 Bernstein
Gilead upgraded to Outperform from Market Perform at Bernstein
03/30/21 Redburn
Gilead upgraded to Buy from Neutral at Redburn
03/15/21 Mizuho
Merck's Gilead collaboration likely to broaden reach of islatravir, says Mizuho
TMO Thermo Fisher
$469.09 /

+3.53 (+0.76%)

03/29/21 UBS
Thermo Fisher price target lowered to $560 from $588 at UBS
03/18/21 KeyBanc
Thermo Fisher upgraded to Overweight at KeyBanc after Sartorius guidance
03/18/21 KeyBanc
Thermo Fisher upgraded to Overweight from Sector Weight at KeyBanc
03/02/21 Barclays
Thermo Fisher initiated with an Overweight at Barclays
SGTX Sigilon Therapeutics
$19.05 /

-0.965 (-4.82%)

12/29/20 Barclays
Sigilon Therapeutics initiated with an Overweight at Barclays
12/29/20 Morgan Stanley
Sigilon Therapeutics initiated with an Equal Weight at Morgan Stanley
12/29/20 Jefferies
Sigilon Therapeutics initiated with a Buy at Jefferies
ADAP Adaptimmune
$5.26 /

-0.35 (-6.24%)

08/12/20 Piper Sandler
TCR2 Therapeutics initiated with an Overweight at Piper Sandler
06/01/20 Mizuho
Adaptimmune price target raised to $9 from $3 at Mizuho
05/29/20 JonesTrading
JonesTrading upgrades Adaptimmune to Buy after data alleviates 'key concern'
05/29/20 JonesTrading
Adaptimmune upgraded to Buy from Hold at JonesTrading
AGTC Applied Genetic
$4.74 /

-0.26 (-5.20%)

03/01/21 Stifel
Applied Genetic initiated with a Buy at Stifel
02/02/21 H.C. Wainwright
Applied Genetic price target raised to $24 from $18 at H.C. Wainwright
02/01/21 Roth Capital
Applied Genetic price target raised to $35 from $30 at Roth Capital
11/17/20 Roth Capital
Applied Genetic price target raised to $30 from $26 at Roth Capital
ATRA Atara Biotherapeutics
$14.15 /

-0.53 (-3.61%)

03/25/21 Evercore ISI
Viracta Therapeutics initiated with an Outperform at Evercore ISI
03/02/21 Citi
Atara Biotherapeutics upgraded to Buy at Citi following 35% pullback
03/02/21 Citi
Atara Biotherapeutics upgraded to Buy from Neutral at Citi
01/04/21 Roth Capital
Roth keeps Buy rating on Atara Biotherapeutics after filing delay
CABA Cabaletta Bio
$11.21 /

-0.4 (-3.45%)

03/17/21 H.C. Wainwright
Cabaletta Bio price target raised to $22 from $20 at H.C. Wainwright
01/08/21 Chardan
Cabaletta Bio initiated with a Buy at Chardan
10/13/20 H.C. Wainwright
Cabaletta Bio initiated with a Buy at H.C. Wainwright
FLXN Flexion
$8.71 /

-0.11 (-1.25%)

04/06/21 RBC Capital
Flexion transferred with an Outperform at RBC Capital
08/20/20 Goldman Sachs
Flexion initiated with a Neutral at Goldman Sachs
07/30/20 Oppenheimer
Flexion initiated with an Outperform at Oppenheimer
07/29/20
Fly Intel: Top five analyst initiations
DTIL Precision BioSciences
$9.23 /

-1.24 (-11.84%)

04/06/21 Stifel
Stifel sees Precision BioSciences' CEO transition as 'disconcerting'
02/24/21
Fly Intel: Top five analyst initiations
02/24/21 JonesTrading
Precision BioSciences initiated with a Buy at JonesTrading
01/29/21 JPMorgan
Precision BioSciences price target raised to $14 from $10 at JPMorgan
DOV Dover
$139.44 /

-0.74 (-0.53%)

04/06/21 Barclays
Dover price target raised to $155 from $145 at Barclays
01/28/21 Baird
Dover price target raised to $147 from $140 at Baird
01/28/21 Baird
Dover results a solid beat with guidance above consensus, says Baird
01/05/21 Barclays
Dover price target raised to $141 from $138 at Barclays
GNPX Genprex
$4.29 /

+0.06 (+1.42%)

01/26/21 National Securities
Genprex initiated with a Buy at National Securities
04/22/20 Alliance Global Partners
Genprex initiated with a Buy at Alliance Global Partners
DBTX Decibel Therapeutics
$11.48 /

+0.09 (+0.79%)

03/09/21 Citi
Decibel Therapeutics initiated with a Buy at Citi
03/09/21 SVB Leerink
Decibel Therapeutics initiated with an Outperform at SVB Leerink
03/09/21 Barclays
Decibel Therapeutics initiated with an Overweight at Barclays
03/09/21 BMO Capital
Decibel Therapeutics initiated with an Outperform at BMO Capital
CYRX Cryoport
$51.47 /

+1.1 (+2.18%)

03/15/21
Fly Intel: Top five analyst initiations
03/15/21 UBS
Cryoport initiated with a Buy at UBS
03/02/21
Fly Intel: Top five analyst initiations
03/02/21 Needham
Cryoport assumed with a Buy at Needham
GLW Corning
$44.68 /

-0.81 (-1.78%)

01/28/21 Oppenheimer
Corning upgraded to Outperform from Perform at Oppenheimer
01/14/21 Barclays
Corning upgraded to Overweight with $44 target at Barclays
01/14/21 Barclays
Corning upgraded to Overweight from Equal Weight at Barclays
01/06/21
Fly Intel: Top five analyst initiations
FTV Fortive
$71.18 /

-0.78 (-1.08%)

04/06/21 Barclays
Fortive price target raised to $73 from $72 at Barclays
02/17/21
Fly Intel: Top five analyst downgrades
02/17/21 Morgan Stanley
Fortive downgraded to Equal Weight at Morgan Stanley after re-rating
02/17/21 Morgan Stanley
Fortive downgraded to Equal Weight from Overweight at Morgan Stanley
KRYS Krystal Biotech
$74.13 /

-4.6 (-5.84%)

03/01/21 H.C. Wainwright
Krystal Biotech price target raised to $103 from $84 at H.C. Wainwright
03/01/21 William Blair
Krystal Biotech has 'catalyst-rich year ahead,' says William Blair
02/09/21 JonesTrading
Krystal Biotech initiated with a Buy at JonesTrading
01/15/21 Chardan
Krystal Biotech named a 'Top Pick for 2021' at Chardan
NVO Novo Nordisk
$68.05 /

-0.235 (-0.34%)

02/11/21 UBS
Novo Nordisk price target raised to DKK 425 from DKK 415 at UBS
02/04/21 Barclays
Novo Nordisk price target raised to DKK 495 from DKK 485 at Barclays
01/20/21 Citi
Citi opens 'Positive Catalyst Watch' on Novo Nordisk
01/20/21 Credit Suisse
Novo Nordisk downgraded to Neutral from Outperform at Credit Suisse
NVS Novartis
$86.40 /

-0.89 (-1.02%)

04/05/21 Morgan Stanley
Regenxbio AAV9 patent challenged by Passage Bio, says Morgan Stanley
03/23/21 Societe Generale
Novartis price target raised to CHF 107 from CHF 104 at Societe Generale
03/22/21 Bernstein
Novartis initiated with a Market Perform at Bernstein
03/10/21
Fly Intel: Top five analyst downgrades
ORTX Orchard Therapeutics
$7.09 /

-0.14 (-1.94%)

03/10/21 Stifel
Stifel says Bluebird update on AML provides 'some relief' to other LV players
03/02/21 JPMorgan
Orchard Therapeutics assumed with an Overweight at JPMorgan
03/01/21 Stifel
Orchard Therapeutics initiated with a Buy at Stifel
02/18/21 Goldman Sachs
Orchard selloff on Bluebird Bio news overdone, says Goldman Sachs
MRK Merck
$75.79 /

-1.21 (-1.57%)

04/06/21 RBC Capital
Merck transferred with a Sector Perform at RBC Capital
04/01/21 Morgan Stanley
Merck cancer pipeline underappreciated and 'set to flow,' says Morgan Stanley
03/15/21 Piper Sandler
Gilead pact with Merck can bring HIV sustainability, says Piper Sandler
MEDP Medpace
$171.71 /

+0.78 (+0.46%)

02/17/21 Truist
Medpace price target raised to $180 from $135 at Truist
02/16/21 Credit Suisse
Medpace price target raised to $178 from $155 at Credit Suisse
10/02/20 Truist
Medpace upgraded to Buy from Hold at Truist
07/29/20 Truist
Medpace price target raised to $124 from $95 at SunTrust
IOVA Iovance Biotherapeutics
$31.99 /

-0.16 (-0.50%)

03/08/21 H.C. Wainwright
Iovance Biotherapeutics upgraded to Buy from Neutral at H.C. Wainwright
01/29/21 Baird
Iovance Biotherapeutics assumed at Outperform at Baird
01/14/21 Oppenheimer
Iovance Biotherapeutics price target raised to $57 from $43 at Oppenheimer
12/17/20 Barclays
Iovance Biotherapeutics price target raised to $55 from $43 at Barclays
FOLD Amicus
$9.56 /

-0.3848 (-3.87%)

03/01/21 Stifel
Amicus initiated with a Hold at Stifel
02/12/21
Fly Intel: Top five analyst downgrades
02/12/21 JPMorgan
Amicus downgraded to Neutral on Pompe disease miss at JPMorgan
02/12/21 SVB Leerink
Amicus downgraded to Market Perform from Outperform at SVB Leerink
TMO Thermo Fisher
$469.09 /

+3.53 (+0.76%)

SGTX Sigilon Therapeutics
$19.05 /

-0.965 (-4.82%)

ORTX Orchard Therapeutics
$7.09 /

-0.14 (-1.94%)

NVS Novartis
$86.40 /

-0.89 (-1.02%)

NVO Novo Nordisk
$68.05 /

-0.235 (-0.34%)

MRK Merck
$75.79 /

-1.21 (-1.57%)

MEDP Medpace
$171.71 /

+0.78 (+0.46%)

KRYS Krystal Biotech
$74.13 /

-4.6 (-5.84%)

IOVA Iovance Biotherapeutics
$31.99 /

-0.16 (-0.50%)

GLW Corning
$44.68 /

-0.81 (-1.78%)

GILD Gilead
$66.26 /

-0.09 (-0.14%)

FTV Fortive
$71.18 /

-0.78 (-1.08%)

FOLD Amicus
$9.56 /

-0.3848 (-3.87%)

FLXN Flexion
$8.71 /

-0.11 (-1.25%)

DTIL Precision BioSciences
$9.23 /

-1.24 (-11.84%)

DOV Dover
$139.44 /

-0.74 (-0.53%)

CYRX Cryoport
$51.47 /

+1.1 (+2.18%)

CABA Cabaletta Bio
$11.21 /

-0.4 (-3.45%)

BLUE Bluebird Bio
$30.15 /

-0.95 (-3.05%)

ATRA Atara Biotherapeutics
$14.15 /

-0.53 (-3.61%)

AGTC Applied Genetic
$4.74 /

-0.26 (-5.20%)

ADAP Adaptimmune
$5.26 /

-0.35 (-6.24%)

  • 12
    Feb
  • 03
    Feb
  • 28
    Jan
  • 21
    Jan
  • 09
    Dec
  • 04
    Dec
  • 02
    Jun
  • 29
    May
  • 27
    May
  • 21
    May
  • 19
    May
  • 19
    May
TMO Thermo Fisher
$469.09 /

+3.53 (+0.76%)

NVS Novartis
$86.40 /

-0.89 (-1.02%)

MRK Merck
$75.79 /

-1.21 (-1.57%)

GLW Corning
$44.68 /

-0.81 (-1.78%)

GILD Gilead
$66.26 /

-0.09 (-0.14%)

FTV Fortive
$71.18 /

-0.78 (-1.08%)

FOLD Amicus
$9.56 /

-0.3848 (-3.87%)

CYRX Cryoport
$51.47 /

+1.1 (+2.18%)

BLUE Bluebird Bio
$30.15 /

-0.95 (-3.05%)

TMO Thermo Fisher
$469.09 /

+3.53 (+0.76%)

SGTX Sigilon Therapeutics
$19.05 /

-0.965 (-4.82%)

NVS Novartis
$86.40 /

-0.89 (-1.02%)

MRK Merck
$75.79 /

-1.21 (-1.57%)

GLW Corning
$44.68 /

-0.81 (-1.78%)

GILD Gilead
$66.26 /

-0.09 (-0.14%)

FOLD Amicus
$9.56 /

-0.3848 (-3.87%)

DTIL Precision BioSciences
$9.23 /

-1.24 (-11.84%)

DOV Dover
$139.44 /

-0.74 (-0.53%)

DBTX Decibel Therapeutics
$11.48 /

+0.09 (+0.79%)

BLUE Bluebird Bio
$30.15 /

-0.95 (-3.05%)

ATRA Atara Biotherapeutics
$14.15 /

-0.53 (-3.61%)

AGTC Applied Genetic
$4.74 /

-0.26 (-5.20%)

NVO Novo Nordisk
$68.05 /

-0.235 (-0.34%)

MRK Merck
$75.79 /

-1.21 (-1.57%)

IOVA Iovance Biotherapeutics
$31.99 /

-0.16 (-0.50%)

GLW Corning
$44.68 /

-0.81 (-1.78%)

GILD Gilead
$66.26 /

-0.09 (-0.14%)

FOLD Amicus
$9.56 /

-0.3848 (-3.87%)

CABA Cabaletta Bio
$11.21 /

-0.4 (-3.45%)

BLUE Bluebird Bio
$30.15 /

-0.95 (-3.05%)

Conference/Events
Alliance for Regenerative Medicine to hold a virtual meeting » 09:55
04/06/21
04/06
09:55
04/06/21
09:55
BLUE

Bluebird Bio

$30.45 /

-0.65 (-2.09%)

, GILD

Gilead

$66.10 /

-0.25 (-0.38%)

, TMO

Thermo Fisher

$465.69 /

+0.13 (+0.03%)

, SGTX

Sigilon Therapeutics

$20.04 /

+0.02 (+0.10%)

, ADAP

Adaptimmune

$5.58 /

-0.03 (-0.53%)

, AGTC

Applied Genetic

$4.95 /

-0.05 (-1.00%)

, ATRA

Atara Biotherapeutics

$14.68 /

+ (+0.00%)

, CABA

Cabaletta Bio

$11.61 /

+ (+0.00%)

, FLXN

Flexion

$8.65 /

-0.17 (-1.93%)

, DTIL

Precision BioSciences

$10.30 /

-0.17 (-1.62%)

, DOV

Dover

$140.45 /

+0.27 (+0.19%)

, GNPX

Genprex

$4.14 /

-0.09 (-2.13%)

, DBTX

Decibel Therapeutics

$11.36 /

-0.03 (-0.26%)

, CYRX

Cryoport

$50.71 /

+0.34 (+0.68%)

, GLW

Corning

$45.30 /

-0.19 (-0.42%)

, FTV

Fortive

$72.04 /

+0.08 (+0.11%)

, KRYS

Krystal Biotech

$78.76 /

+0.03 (+0.04%)

, NVO

Novo Nordisk

$68.09 /

-0.19 (-0.28%)

, NVS

Novartis

$87.06 /

-0.23 (-0.26%)

, ORTX

Orchard Therapeutics

$7.19 /

-0.04 (-0.55%)

, MRK

Merck

$76.44 /

-0.56 (-0.73%)

, MEDP

Medpace

$173.03 /

+2.1 (+1.23%)

, IOVA

Iovance Biotherapeutics

$31.80 /

-0.35 (-1.09%)

, FOLD

Amicus

$9.89 /

-0.055 (-0.55%)

Cell & Gene Virtual…

Cell & Gene Virtual Meeting on the Mediterranean will be held on April 6-9. Webcast Link

ShowHide Related Items >><<
TMO Thermo Fisher
$465.69 /

+0.13 (+0.03%)

SGTX Sigilon Therapeutics
$20.04 /

+0.02 (+0.10%)

ORTX Orchard Therapeutics
$7.19 /

-0.04 (-0.55%)

NVS Novartis
$87.06 /

-0.23 (-0.26%)

NVO Novo Nordisk
$68.09 /

-0.19 (-0.28%)

MRK Merck
$76.44 /

-0.56 (-0.73%)

KRYS Krystal Biotech
$78.76 /

+0.03 (+0.04%)

IOVA Iovance Biotherapeutics
$31.80 /

-0.35 (-1.09%)

GNPX Genprex
$4.14 /

-0.09 (-2.13%)

GLW Corning
$45.30 /

-0.19 (-0.42%)

GILD Gilead
$66.10 /

-0.25 (-0.38%)

FTV Fortive
$72.04 /

+0.08 (+0.11%)

FOLD Amicus
$9.89 /

-0.055 (-0.55%)

FLXN Flexion
$8.65 /

-0.17 (-1.93%)

DTIL Precision BioSciences
$10.30 /

-0.17 (-1.62%)

DOV Dover
$140.45 /

+0.27 (+0.19%)

DBTX Decibel Therapeutics
$11.36 /

-0.03 (-0.26%)

CYRX Cryoport
$50.71 /

+0.34 (+0.68%)

CABA Cabaletta Bio
$11.61 /

+ (+0.00%)

BLUE Bluebird Bio
$30.45 /

-0.65 (-2.09%)

ATRA Atara Biotherapeutics
$14.68 /

+ (+0.00%)

AGTC Applied Genetic
$4.95 /

-0.05 (-1.00%)

ADAP Adaptimmune
$5.58 /

-0.03 (-0.53%)

BLUE Bluebird Bio
$30.45 /

-0.65 (-2.09%)

03/29/21 BMO Capital
Bluebird Bio price target raised to $35 from $31 at BMO Capital
03/29/21 Mizuho
Bluebird Bio approval could improve sentiment on shares, says Mizuho
03/29/21 Piper Sandler
Bluebird Bio price target raised to $35 from $30 at Piper Sandler
03/17/21 Stifel
Stifel says Bluebird Bio CMO exit 'a bit concerning but not thesis changing'
GILD Gilead
$66.10 /

-0.25 (-0.38%)

04/01/21
Fly Intel: Top five analyst upgrades
04/01/21 Bernstein
Gilead upgraded to Outperform from Market Perform at Bernstein
03/30/21 Redburn
Gilead upgraded to Buy from Neutral at Redburn
03/15/21 Mizuho
Merck's Gilead collaboration likely to broaden reach of islatravir, says Mizuho
TMO Thermo Fisher
$465.69 /

+0.13 (+0.03%)

03/29/21 UBS
Thermo Fisher price target lowered to $560 from $588 at UBS
03/18/21 KeyBanc
Thermo Fisher upgraded to Overweight at KeyBanc after Sartorius guidance
03/18/21 KeyBanc
Thermo Fisher upgraded to Overweight from Sector Weight at KeyBanc
03/02/21 Barclays
Thermo Fisher initiated with an Overweight at Barclays
SGTX Sigilon Therapeutics
$20.04 /

+0.02 (+0.10%)

12/29/20 Barclays
Sigilon Therapeutics initiated with an Overweight at Barclays
12/29/20 Morgan Stanley
Sigilon Therapeutics initiated with an Equal Weight at Morgan Stanley
12/29/20 Jefferies
Sigilon Therapeutics initiated with a Buy at Jefferies
ADAP Adaptimmune
$5.58 /

-0.03 (-0.53%)

08/12/20 Piper Sandler
TCR2 Therapeutics initiated with an Overweight at Piper Sandler
06/01/20 Mizuho
Adaptimmune price target raised to $9 from $3 at Mizuho
05/29/20 JonesTrading
JonesTrading upgrades Adaptimmune to Buy after data alleviates 'key concern'
05/29/20 JonesTrading
Adaptimmune upgraded to Buy from Hold at JonesTrading
AGTC Applied Genetic
$4.95 /

-0.05 (-1.00%)

03/01/21 Stifel
Applied Genetic initiated with a Buy at Stifel
02/02/21 H.C. Wainwright
Applied Genetic price target raised to $24 from $18 at H.C. Wainwright
02/01/21 Roth Capital
Applied Genetic price target raised to $35 from $30 at Roth Capital
11/17/20 Roth Capital
Applied Genetic price target raised to $30 from $26 at Roth Capital
ATRA Atara Biotherapeutics
$14.68 /

+ (+0.00%)

03/25/21 Evercore ISI
Viracta Therapeutics initiated with an Outperform at Evercore ISI
03/02/21 Citi
Atara Biotherapeutics upgraded to Buy at Citi following 35% pullback
03/02/21 Citi
Atara Biotherapeutics upgraded to Buy from Neutral at Citi
01/04/21 Roth Capital
Roth keeps Buy rating on Atara Biotherapeutics after filing delay
CABA Cabaletta Bio
$11.61 /

+ (+0.00%)

03/17/21 H.C. Wainwright
Cabaletta Bio price target raised to $22 from $20 at H.C. Wainwright
01/08/21 Chardan
Cabaletta Bio initiated with a Buy at Chardan
10/13/20 H.C. Wainwright
Cabaletta Bio initiated with a Buy at H.C. Wainwright
FLXN Flexion
$8.65 /

-0.17 (-1.93%)

08/20/20 Goldman Sachs
Flexion initiated with a Neutral at Goldman Sachs
07/30/20 Oppenheimer
Flexion initiated with an Outperform at Oppenheimer
07/29/20
Fly Intel: Top five analyst initiations
07/29/20 Credit Suisse
Flexion initiated with an Outperform at Credit Suisse
DTIL Precision BioSciences
$10.30 /

-0.17 (-1.62%)

02/24/21
Fly Intel: Top five analyst initiations
02/24/21 JonesTrading
Precision BioSciences initiated with a Buy at JonesTrading
01/29/21 JPMorgan
Precision BioSciences price target raised to $14 from $10 at JPMorgan
12/15/20 H.C. Wainwright
Precision BioSciences transferred with Buy rating at H.C. Wainwright
DOV Dover
$140.45 /

+0.27 (+0.19%)

04/06/21 Barclays
Dover price target raised to $155 from $145 at Barclays
01/28/21 Baird
Dover price target raised to $147 from $140 at Baird
01/28/21 Baird
Dover results a solid beat with guidance above consensus, says Baird
01/05/21 Barclays
Dover price target raised to $141 from $138 at Barclays
GNPX Genprex
$4.14 /

-0.09 (-2.13%)

01/26/21 National Securities
Genprex initiated with a Buy at National Securities
04/22/20 Alliance Global Partners
Genprex initiated with a Buy at Alliance Global Partners
DBTX Decibel Therapeutics
$11.36 /

-0.03 (-0.26%)

03/09/21 Citi
Decibel Therapeutics initiated with a Buy at Citi
03/09/21 SVB Leerink
Decibel Therapeutics initiated with an Outperform at SVB Leerink
03/09/21 Barclays
Decibel Therapeutics initiated with an Overweight at Barclays
03/09/21 BMO Capital
Decibel Therapeutics initiated with an Outperform at BMO Capital
CYRX Cryoport
$50.71 /

+0.34 (+0.68%)

03/15/21
Fly Intel: Top five analyst initiations
03/15/21 UBS
Cryoport initiated with a Buy at UBS
03/02/21
Fly Intel: Top five analyst initiations
03/02/21 Needham
Cryoport assumed with a Buy at Needham
GLW Corning
$45.30 /

-0.19 (-0.42%)

01/28/21 Oppenheimer
Corning upgraded to Outperform from Perform at Oppenheimer
01/14/21 Barclays
Corning upgraded to Overweight with $44 target at Barclays
01/14/21 Barclays
Corning upgraded to Overweight from Equal Weight at Barclays
01/06/21
Fly Intel: Top five analyst initiations
FTV Fortive
$72.04 /

+0.08 (+0.11%)

04/06/21 Barclays
Fortive price target raised to $73 from $72 at Barclays
02/17/21
Fly Intel: Top five analyst downgrades
02/17/21 Morgan Stanley
Fortive downgraded to Equal Weight at Morgan Stanley after re-rating
02/17/21 Morgan Stanley
Fortive downgraded to Equal Weight from Overweight at Morgan Stanley
KRYS Krystal Biotech
$78.76 /

+0.03 (+0.04%)

03/01/21 H.C. Wainwright
Krystal Biotech price target raised to $103 from $84 at H.C. Wainwright
03/01/21 William Blair
Krystal Biotech has 'catalyst-rich year ahead,' says William Blair
02/09/21 JonesTrading
Krystal Biotech initiated with a Buy at JonesTrading
01/15/21 Chardan
Krystal Biotech named a 'Top Pick for 2021' at Chardan
NVO Novo Nordisk
$68.09 /

-0.19 (-0.28%)

02/11/21 UBS
Novo Nordisk price target raised to DKK 425 from DKK 415 at UBS
02/04/21 Barclays
Novo Nordisk price target raised to DKK 495 from DKK 485 at Barclays
01/20/21 Citi
Citi opens 'Positive Catalyst Watch' on Novo Nordisk
01/20/21 Credit Suisse
Novo Nordisk downgraded to Neutral from Outperform at Credit Suisse
NVS Novartis
$87.06 /

-0.23 (-0.26%)

04/05/21 Morgan Stanley
Regenxbio AAV9 patent challenged by Passage Bio, says Morgan Stanley
03/23/21 Societe Generale
Novartis price target raised to CHF 107 from CHF 104 at Societe Generale
03/22/21 Bernstein
Novartis initiated with a Market Perform at Bernstein
03/10/21
Fly Intel: Top five analyst downgrades
ORTX Orchard Therapeutics
$7.19 /

-0.04 (-0.55%)

03/10/21 Stifel
Stifel says Bluebird update on AML provides 'some relief' to other LV players
03/02/21 JPMorgan
Orchard Therapeutics assumed with an Overweight at JPMorgan
03/01/21 Stifel
Orchard Therapeutics initiated with a Buy at Stifel
02/18/21 Goldman Sachs
Orchard selloff on Bluebird Bio news overdone, says Goldman Sachs
MRK Merck
$76.44 /

-0.56 (-0.73%)

04/01/21 Morgan Stanley
Merck cancer pipeline underappreciated and 'set to flow,' says Morgan Stanley
03/15/21 Piper Sandler
Gilead pact with Merck can bring HIV sustainability, says Piper Sandler
02/25/21 SVB Leerink
Pandion Therapeutics downgraded to Market Perform from Outperform at SVB Leerink
MEDP Medpace
$173.03 /

+2.1 (+1.23%)

02/17/21 Truist
Medpace price target raised to $180 from $135 at Truist
02/16/21 Credit Suisse
Medpace price target raised to $178 from $155 at Credit Suisse
10/02/20 Truist
Medpace upgraded to Buy from Hold at Truist
07/29/20 Truist
Medpace price target raised to $124 from $95 at SunTrust
IOVA Iovance Biotherapeutics
$31.80 /

-0.35 (-1.09%)

03/08/21 H.C. Wainwright
Iovance Biotherapeutics upgraded to Buy from Neutral at H.C. Wainwright
01/29/21 Baird
Iovance Biotherapeutics assumed at Outperform at Baird
01/14/21 Oppenheimer
Iovance Biotherapeutics price target raised to $57 from $43 at Oppenheimer
12/17/20 Barclays
Iovance Biotherapeutics price target raised to $55 from $43 at Barclays
FOLD Amicus
$9.89 /

-0.055 (-0.55%)

03/01/21 Stifel
Amicus initiated with a Hold at Stifel
02/12/21
Fly Intel: Top five analyst downgrades
02/12/21 JPMorgan
Amicus downgraded to Neutral on Pompe disease miss at JPMorgan
02/12/21 SVB Leerink
Amicus downgraded to Market Perform from Outperform at SVB Leerink
TMO Thermo Fisher
$465.69 /

+0.13 (+0.03%)

SGTX Sigilon Therapeutics
$20.04 /

+0.02 (+0.10%)

ORTX Orchard Therapeutics
$7.19 /

-0.04 (-0.55%)

NVS Novartis
$87.06 /

-0.23 (-0.26%)

NVO Novo Nordisk
$68.09 /

-0.19 (-0.28%)

MRK Merck
$76.44 /

-0.56 (-0.73%)

MEDP Medpace
$173.03 /

+2.1 (+1.23%)

KRYS Krystal Biotech
$78.76 /

+0.03 (+0.04%)

IOVA Iovance Biotherapeutics
$31.80 /

-0.35 (-1.09%)

GLW Corning
$45.30 /

-0.19 (-0.42%)

GILD Gilead
$66.10 /

-0.25 (-0.38%)

FTV Fortive
$72.04 /

+0.08 (+0.11%)

FOLD Amicus
$9.89 /

-0.055 (-0.55%)

FLXN Flexion
$8.65 /

-0.17 (-1.93%)

DTIL Precision BioSciences
$10.30 /

-0.17 (-1.62%)

DOV Dover
$140.45 /

+0.27 (+0.19%)

CYRX Cryoport
$50.71 /

+0.34 (+0.68%)

CABA Cabaletta Bio
$11.61 /

+ (+0.00%)

BLUE Bluebird Bio
$30.45 /

-0.65 (-2.09%)

ATRA Atara Biotherapeutics
$14.68 /

+ (+0.00%)

AGTC Applied Genetic
$4.95 /

-0.05 (-1.00%)

ADAP Adaptimmune
$5.58 /

-0.03 (-0.53%)

  • 12
    Feb
  • 03
    Feb
  • 28
    Jan
  • 21
    Jan
  • 09
    Dec
  • 04
    Dec
  • 02
    Jun
  • 29
    May
  • 27
    May
  • 21
    May
  • 19
    May
  • 19
    May
TMO Thermo Fisher
$465.69 /

+0.13 (+0.03%)

NVS Novartis
$87.06 /

-0.23 (-0.26%)

MRK Merck
$76.44 /

-0.56 (-0.73%)

GLW Corning
$45.30 /

-0.19 (-0.42%)

GILD Gilead
$66.10 /

-0.25 (-0.38%)

FTV Fortive
$72.04 /

+0.08 (+0.11%)

FOLD Amicus
$9.89 /

-0.055 (-0.55%)

CYRX Cryoport
$50.71 /

+0.34 (+0.68%)

BLUE Bluebird Bio
$30.45 /

-0.65 (-2.09%)

TMO Thermo Fisher
$465.69 /

+0.13 (+0.03%)

SGTX Sigilon Therapeutics
$20.04 /

+0.02 (+0.10%)

NVS Novartis
$87.06 /

-0.23 (-0.26%)

MRK Merck
$76.44 /

-0.56 (-0.73%)

IOVA Iovance Biotherapeutics
$31.80 /

-0.35 (-1.09%)

GLW Corning
$45.30 /

-0.19 (-0.42%)

GILD Gilead
$66.10 /

-0.25 (-0.38%)

FOLD Amicus
$9.89 /

-0.055 (-0.55%)

DTIL Precision BioSciences
$10.30 /

-0.17 (-1.62%)

DOV Dover
$140.45 /

+0.27 (+0.19%)

DBTX Decibel Therapeutics
$11.36 /

-0.03 (-0.26%)

BLUE Bluebird Bio
$30.45 /

-0.65 (-2.09%)

ATRA Atara Biotherapeutics
$14.68 /

+ (+0.00%)

AGTC Applied Genetic
$4.95 /

-0.05 (-1.00%)

NVO Novo Nordisk
$68.09 /

-0.19 (-0.28%)

MRK Merck
$76.44 /

-0.56 (-0.73%)

IOVA Iovance Biotherapeutics
$31.80 /

-0.35 (-1.09%)

GLW Corning
$45.30 /

-0.19 (-0.42%)

GILD Gilead
$66.10 /

-0.25 (-0.38%)

FOLD Amicus
$9.89 /

-0.055 (-0.55%)

CABA Cabaletta Bio
$11.61 /

+ (+0.00%)

BLUE Bluebird Bio
$30.45 /

-0.65 (-2.09%)

On The Fly
Fly Intel: Pre-market Movers » 08:56
03/29/21
03/29
08:56
03/29/21
08:56
FLY

Fly Leasing

$13.26 /

-0.34 (-2.50%)

, HGEN

Humanigen

$14.00 /

+0.25 (+1.82%)

, BLUE

Bluebird Bio

$29.97 /

+0.33 (+1.11%)

, TME

Tencent Music

$20.05 /

-0.3 (-1.47%)

, TWTR

Twitter

$61.32 /

+0.14 (+0.23%)

, CS

Credit Suisse

$12.87 /

-0.345 (-2.61%)

, ORPH

Orphazyme

$12.39 /

+0.03 (+0.24%)

, AGRO

Adecoagro

$7.90 /

-0.11 (-1.37%)

, NMR

Nomura

$6.62 /

+0.02 (+0.30%)

, BMY

Bristol-Myers

$63.94 /

+1.16 (+1.85%)

Check out this morning's…

ShowHide Related Items >><<
TWTR Twitter
$61.32 /

+0.14 (+0.23%)

TME Tencent Music
$20.05 /

-0.3 (-1.47%)

ORPH Orphazyme
$12.39 /

+0.03 (+0.24%)

NMR Nomura
$6.62 /

+0.02 (+0.30%)

HGEN Humanigen
$14.00 /

+0.25 (+1.82%)

FLY Fly Leasing
$13.26 /

-0.34 (-2.50%)

CS Credit Suisse
$12.87 /

-0.345 (-2.61%)

BMY Bristol-Myers
$63.94 /

+1.16 (+1.85%)

BLUE Bluebird Bio
$29.97 /

+0.33 (+1.11%)

FLY Fly Leasing
$13.26 /

-0.34 (-2.50%)

03/19/21 Deutsche Bank
Fly Leasing price target raised to $13 from $10 at Deutsche Bank
02/26/21 Deutsche Bank
Fly Leasing downgraded to Hold with $10 target at Deutsche Bank
02/26/21 Deutsche Bank
Fly Leasing downgraded to Hold from Buy at Deutsche Bank
01/26/21 Cowen
Fly Leasing price target raised to $13 from $9 at Cowen
HGEN Humanigen
$14.00 /

+0.25 (+1.82%)

02/23/21 JPMorgan
Humanigen initiated with a Neutral at JPMorgan
01/20/21 Jefferies
Jefferies reads Humanigen COVID-19 trial change as 'sign of confidence'
12/23/20 National Securities
Humanigen initiated with a Buy at National Securities
12/22/20
Fly Intel: Top five analyst initiations
BLUE Bluebird Bio
$29.97 /

+0.33 (+1.11%)

03/29/21 BMO Capital
Bluebird Bio price target raised to $35 from $31 at BMO Capital
03/29/21 Mizuho
Bluebird Bio approval could improve sentiment on shares, says Mizuho
03/29/21 Piper Sandler
Bluebird Bio price target raised to $35 from $30 at Piper Sandler
03/17/21 Stifel
Stifel says Bluebird Bio CMO exit 'a bit concerning but not thesis changing'
TME Tencent Music
$20.05 /

-0.3 (-1.47%)

03/25/21
Fly Intel: Top five analyst downgrades
03/24/21 Goldman Sachs
Goldman downgrades Tencent Music to Neutral after 65% year-to-date rally
03/24/21 Goldman Sachs
Tencent Music downgraded to Neutral from Buy at Goldman Sachs
03/24/21 HSBC
Tencent Music price target raised to $35 from $30 at HSBC
TWTR Twitter
$61.32 /

+0.14 (+0.23%)

03/29/21 Truist
Twitter upgraded to Buy from Hold at Truist
03/29/21 Truist
Twitter upgraded to Buy from Hold at Truist
03/16/21 Citi
Twitter price target raised to $80 from $55 at Citi
03/08/21 Oppenheimer
Too soon to tell impact of Chrome policy changes on e-commerce, says Oppenheimer
CS Credit Suisse
$12.87 /

-0.345 (-2.61%)

03/29/21 BofA
Credit Suisse downgraded to Neutral from Buy at BofA
03/17/21 Kepler Cheuvreux
Credit Suisse downgraded to Hold from Buy at Kepler Cheuvreux
03/11/21 Goldman Sachs
Credit Suisse downgraded to Neutral from Buy at Goldman Sachs
02/23/21 JPMorgan
Credit Suisse price target raised to CHF 15 from CHF 14 at JPMorgan
ORPH Orphazyme
$12.39 /

+0.03 (+0.24%)

10/26/20 Guggenheim
Orphazyme initiated with a Buy at Guggenheim
10/26/20 BofA
Orphazyme initiated with a Buy at BofA
10/26/20 BofA
Orphazyme initiated with a Buy at BofA
AGRO Adecoagro
$7.90 /

-0.11 (-1.37%)

03/29/21 Morgan Stanley
Morgan Stanley downgrades Adecoagro, sees limited near-term sugar price upside
03/29/21 Morgan Stanley
Adecoagro downgraded to Equal Weight from Overweight at Morgan Stanley
06/02/20 JPMorgan
Adecoagro reinstated with an Overweight at JPMorgan
NMR Nomura
$6.62 /

+0.02 (+0.30%)

03/29/21 JPMorgan
Nomura downgraded to Underweight from Neutral at JPMorgan
03/09/21 Goldman Sachs
Nomura upgraded to Buy from Neutral at Goldman Sachs
03/01/21 Citi
Nomura upgraded to Neutral from Sell at Citi
08/04/20 Daiwa
Nomura upgraded to Outperform from Neutral at Daiwa
BMY Bristol-Myers
$63.94 /

+1.16 (+1.85%)

03/08/21 BofA
Gartner added to US 1 List, Bristol-Myers removed at BofA
02/12/21 Morgan Stanley
Amgen court decision may have readthrough for Gilead, says Morgan Stanley
02/02/21 BTIG
Prothena upgraded to Buy at BTIG on birtamimab 'revival'
01/20/21 William Blair
Exelixis selloff on competitive concerns an 'overreaction,' says William Blair
TWTR Twitter
$61.32 /

+0.14 (+0.23%)

TME Tencent Music
$20.05 /

-0.3 (-1.47%)

HGEN Humanigen
$14.00 /

+0.25 (+1.82%)

FLY Fly Leasing
$13.26 /

-0.34 (-2.50%)

CS Credit Suisse
$12.87 /

-0.345 (-2.61%)

BMY Bristol-Myers
$63.94 /

+1.16 (+1.85%)

BLUE Bluebird Bio
$29.97 /

+0.33 (+1.11%)

  • 26
    Mar
  • 26
    Mar
  • 29
    Sep
  • 18
    Sep
  • 19
    May
TWTR Twitter
$61.32 /

+0.14 (+0.23%)

FLY Fly Leasing
$13.26 /

-0.34 (-2.50%)

CS Credit Suisse
$12.87 /

-0.345 (-2.61%)

BMY Bristol-Myers
$63.94 /

+1.16 (+1.85%)

BLUE Bluebird Bio
$29.97 /

+0.33 (+1.11%)

TWTR Twitter
$61.32 /

+0.14 (+0.23%)

ORPH Orphazyme
$12.39 /

+0.03 (+0.24%)

HGEN Humanigen
$14.00 /

+0.25 (+1.82%)

BMY Bristol-Myers
$63.94 /

+1.16 (+1.85%)

BLUE Bluebird Bio
$29.97 /

+0.33 (+1.11%)

TWTR Twitter
$61.32 /

+0.14 (+0.23%)

TME Tencent Music
$20.05 /

-0.3 (-1.47%)

HGEN Humanigen
$14.00 /

+0.25 (+1.82%)

CS Credit Suisse
$12.87 /

-0.345 (-2.61%)

BMY Bristol-Myers
$63.94 /

+1.16 (+1.85%)

BLUE Bluebird Bio
$29.97 /

+0.33 (+1.11%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.